1 - 10 of 28 Search Results for 792
|
|
3.
Coherent
(PAGE 36 OF 156)
|
|
... the write-off of purchased in-process research and development (IPR&D) associated with the acquisitions of DEOS and MicroLas. (2) Includes a $79.2 million after-tax impairment charge on our Lumenis common stock; a $6.7 million aftertax asset impairment charge resulting primarily from a decision ...
Related Searches: microlas
|
|
|
|
|
4.
ACF2686
(PAGE 3 OF 92)
|
|
|
... $1.6 million ($0.7 million after-tax and minority interest or $0.02 per diluted share). The fiscal 2002 impairment charges include a $104.2 million ($79.2 million after-tax) write-down of the value of the Lumenis stock we acquired as a result of the April 2001 sale of our Medical segment to Lumenis as ...
|
|
|
|
|
5.
ACF268A
(PAGE 3 OF 92)
|
|
|
... $1.6 million ($0.7 million after-tax and minority interest or $0.02 per diluted share). The fiscal 2002 impairment charges include a $104.2 million ($79.2 million after-tax) write-down of the value of the Lumenis stock we acquired as a result of the April 2001 sale of our Medical segment to Lumenis as ...
|
|
|
|
|
6.
Coherent_Combo
(PAGE 88 OF 136)
|
|
|
... other relevant criteria and concluded that this decline was other-than-temporary. As a result, we recognized an impairment loss of $104.2 million ($79.2 million after income tax benefit of $25.0 million) in the third quarter of fiscal 2002. The $25.0 million in tax benefit related to the impairment ...
|
|
|
|
|
7.
ACF2686
(PAGE 18 OF 92)
|
|
|
... -tax charge for the write-off of purchased in-process research and development associated with the acquisitions of DEOS and MicroLas. (5) Includes a $79.2 million, or $2.75 per diluted share, after-tax impairment charge on our Lumenis common stock, a $6.7 million, or $0.23 per diluted share, after-tax ...
|
|
|
|
|
8.
ACF268A
(PAGE 18 OF 92)
|
|
|
... -tax charge for the write-off of purchased in-process research and development associated with the acquisitions of DEOS and MicroLas. (5) Includes a $79.2 million, or $2.75 per diluted share, after-tax impairment charge on our Lumenis common stock, a $6.7 million, or $0.23 per diluted share, after-tax ...
|
|
|
|
|
9.
ACF2686
(PAGE 19 OF 92)
|
|
|
... mid-term opportunities no longer justified the investments made. In the year ended September 30, 2002, we also recognized a loss of $104.2 million ($79.2 million after-tax) to reflect the other-than-temporary decline in market value of our investment in Lumenis common stock, acquired as a result of ...
|
|
|
|
|
10.
ACF268A
(PAGE 19 OF 92)
|
|
|
... mid-term opportunities no longer justified the investments made. In the year ended September 30, 2002, we also recognized a loss of $104.2 million ($79.2 million after-tax) to reflect the other-than-temporary decline in market value of our investment in Lumenis common stock, acquired as a result of ...
|
|
Coherent Contact Information